Hans Moebius
Chief Tech/Sci/R&D Officer chez Exciva GmbH
Fortune : 250 661 $ au 31/03/2024
Provenance du réseau au premier degré de Hans Moebius
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 19 | |
Ruprecht-Karls-Universität Heidelberg
10
| College/University | Other Consumer Services | 10 |
Exciva GmbH
 Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet.
2
| Holding Company | Miscellaneous Commercial Services | 2 |
Technische Universität Kaiserslautern
1
| College/University | Other Consumer Services | 1 |
Rodin Therapeutics, Inc.
 Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA.
1
| Subsidiary | Biotechnology | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Hans Moebius via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| MERCK KGAA | Pharmaceuticals: Major | Corporate Officer/Principal | |
| BAYER AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
| DYNAVAX TECHNOLOGIES CORPORATION | Biotechnology | Director of Finance/CFO | |
| ADMA BIOLOGICS, INC. | Biotechnology | Director/Board Member | |
| AFFIMED N.V. | Biotechnology | Director/Board Member | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Stanford University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Undergraduate Degree Undergraduate Degree Doctorate Degree Undergraduate Degree | |
Evonik Operations GmbH
 Evonik Operations GmbH Pharmaceuticals: OtherHealth Technology Evonik Operations GmbH manufactures specialty chemicals. The company was founded on August 23, 2000 and is headquartered in Weatherford, TX. | Pharmaceuticals: Other | President | |
| BIOTEST AG | Pharmaceuticals: Other | Chairman | |
Summit Law Group
 Summit Law Group Miscellaneous Commercial ServicesCommercial Services Summit Law Group is a law firm that focuses on providing quality work to its clients. The private company is based in Seattle, WA and has been recognized as the Law Firm of the Year by Euromoney's Benchmark Litigation. The company removes all unnecessary expenses, such as lavish offices and expensive art, to ensure that clients receive the best services possible. Summit Law Group offers innovative fee arrangements and a value adjustment line on every invoice, allowing clients to adjust fees based on the value of the services provided. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| ATON | Pharmaceuticals: Major | Director/Board Member | |
| University of California, Los Angeles | College/University | Masters Business Admin Doctorate Degree | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree | |
| Hastings College | College/University | Graduate Degree | |
| University of California, Santa Cruz | College/University | Undergraduate Degree | |
Speedel Pharma AG
 Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chief Executive Officer | |
| SPEXIS AG | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Ludwig-Maximilians-Universität München | College/University | Undergraduate Degree | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Chairman | |
| RELYPSA INC | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
| UCLA Anderson School of Management | College/University | Masters Business Admin | |
amcure GmbH
 amcure GmbH BiotechnologyHealth Technology amcure GmbH develops active ingredients for the treatment of angiogenesis-related diseases. It offers a peptide based substance, that targets the tumor specific co-receptors. The company was founded by Matthias Klaften and Alexandra Matzke on December 14, 2011 and is headquartered in Eggenstein-Leopoldshafen, Germany. | Biotechnology | Chief Executive Officer | |
| CYTEIR THERAPEUTICS, INC. | Biotechnology | Corporate Officer/Principal | |
| ALPINE IMMUNE SCIENCES, INC. | Biotechnology | President | |
| SYNLOGIC, INC. | Biotechnology | Chief Operating Officer | |
Lumen Bioscience, Inc.
 Lumen Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Lumen Bioscience, Inc. operates as a clinical stage biotechnology company which engages in the manufacture of therapeutic biologics for oral delivery. It focuses on the development of the blue-green algae Spirulina as an industrial scale production platform. The company was founded by Brian Finrow and James Roberts in 2017 and is headquartered in Seattle, WA. | Pharmaceuticals: Other | Director/Board Member | |
AOBiome Therapeutics, Inc.
 AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director of Finance/CFO | |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Miscellaneous Commercial Services | Director/Board Member | |
| ACHILLES THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
Propel Bio Partners LLC
 Propel Bio Partners LLC Investment ManagersFinance Propel Bio Partners LLC (Propel Bio Partners) is a venture capital firm founded in 2022 by Leen Kawas and Richard Alan Kayne. The firm is headquartered in Los Angeles, California. | Investment Managers | Founder Founder Private Equity Investor | |
Propel Bio Management LLC
 Propel Bio Management LLC Investment ManagersFinance Propel Bio Management LLC provides investment advice. The private company is based in Los Angeles, CA. The company was founded in 2022. Leen Kawas has been the CEO of the company since 2022. | Investment Managers | Portfolio Manager-Equities Chief Executive Officer Portfolio Manager-Equities | |
Neovii Biotech GmbH
 Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | Biotechnology | Chief Executive Officer |
Statistiques
Internationale
| Etats-Unis | 29 |
| Allemagne | 17 |
| Royaume-Uni | 3 |
| Suisse | 3 |
| France | 2 |
Sectorielle
| Health Technology | 31 |
| Consumer Services | 8 |
| Commercial Services | 7 |
| Finance | 4 |
| Process Industries | 3 |
Opérationnelle
| Director/Board Member | 123 |
| Corporate Officer/Principal | 87 |
| Independent Dir/Board Member | 37 |
| Chairman | 36 |
| Chief Executive Officer | 30 |
Relations les plus connectées
| Insiders | |
|---|---|
| George Bickerstaff | 37 |
| Tadataka Yamada | 36 |
| Utz-Hellmuth Felcht | 26 |
| Luis Miguel Cardozo Goytizolo | 20 |
| Barbara Kosacz | 17 |
| Bernhard R. M. Ehmer | 16 |
| Kelly Romano | 16 |
| Joseph Edelman | 15 |
| Peter Gruss | 15 |
| Andrew Gengos | 15 |
| Richard Kayne | 12 |
| Helmut Kraft | 11 |
| Mark Litton | 11 |
| James Johnson | 9 |
| Michael Panzara | 9 |
- Bourse
- Insiders
- Hans Moebius
- Connexions Sociétés
